

Received 12/19/03

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Serial No. 10/022,618	Group Art Unit 1645	Filing Date 12/17/2001	Atty. Docket No. LeA 35 010
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION		Applicant(s) Guid HENNING, et al			

U.S. PATENT DOCUMENTS													
*	DOCUMENT NO.								DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	U1	5	9	3	2	4	1	2	08/03/99	DILLNER			

FOREIGN PATENT DOCUMENTS														
	DOCUMENT NO.								DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
													YES	NO
	F1	9	9	2	1	0	1	4	29/04/99	WO				
	F2	0	0	2	4	7	6	0	04/05/00	WO				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)		
<i>Gu</i>	R1	BERGERON, Human Papillomaviruses Associated with Cervical Intraepithelial Neoplasia, Am. J. Surgical Pathology, 16(7):641-649, 1992
	R2	BUSMANIS, Biomarkers in Carcinoma of the Cervix, Emphasis on Tissue-related Factors and their Potential Prognostic Factors, Ann. Acad. Med Singapore, 1998; 27:641-5
	R3	HANNE, Aberrant Expression of the Cell Cycle Associated Proteins TP53, MDM2, p21, p27, cdk4, Cyclin D1, RB and EGFR in Cervical Carcinomas, Gynecologic Oncology 73:223-228 (1999)
	R4	MITRA, ERBB2 (HER2/neu) Oncogene is Frequently Amplified in Squamous Cell Carcinoma of the Uterine Cervix, Cancer Research 54:637-639, February 1, 1994
	R5	RADHAKRISHNA, The Presence of Human Papillomavirus-16/-18 E6, p53, and Bcl-2 protein in Cervicovaginal Smears from Patients with Invasive Cervical Cancer, Cancer Epidemiology, Biomarkers & Prevention, Vol. 5, 239-335, May 1996
	R6	KERSEMAEKERS, Oncogene Alterations in Carcinomas of the Uterine Cervix: Overexpression of the Epidermal Growth Factor Receptor is Associated with Poor Prognosis, Clinical Cancer Research, Vol. 5, 577-586, March 1999
<i>✓</i>	R7	MUNIRAJAN, The Status of Human Papillomavirus and Tumor Suppressor Genes p53 and p16 in Carcinomas of Uterine Cervix from India, Gynecologic Oncology 69:205-209 (1998)

EXAMINER <i>[Signature]</i>	DATE CONSIDERED <i>10/04/06</i>
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449
(Modified)

U.S. Department of Commerce
Patent and Trademark Office

Serial No.
10/022,618

Group Art Unit
1642

Filing Date
12/17/2001

Atty. Docket No.
Le A 35 010

SUPPLEMENTAL

INFORMATION DISCLOSURE CITATION

Applicant(s) Henning, et al.

JUN 28 2006

U.S. PATENT DOCUMENTS

		DOCUMENT NO.							DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
34	U4	5	7	3	3	7	2	1	03/31/98	Hemstreet, et al.	435	6	12/20/92
	U5	5	7	4	1	6	4	8	04/21/98	Hemstreet, et al.	435	6	02/09/96
	U6	6	0	0	5	2	5	6	12/21/99	McGlynn, et al.	250	559.4	02/12/98
	U7	5	5	4	4	6	5	0	08/13/96	Boon, et al.	128	632	02/14/94
	U8	5	1	0	9	4	2	9	04/28/92	Bacus, et al.	382	6	09/21/87
	U9	6	0	0	7	9	9	6	12/28/99	McNamara, et al.	435	6	07/27/98
	U10	6	2	4	8	0	6	3	06/19/01	Barnhill, et al.	600	300	12/22/97
	U11	20	02	01	23	8	4	5	09/05/02	Henning, et al.	702	19	12/17/01

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.							DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
													YES	NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

34	R22	Valdiguie, P., "Role and Use of Expert Systems Within the Clinical Laboratory", Clinica Chimica Acta, 278: 193-202 (1998)
	R23	Kraeft, S., Sutherland, R., Gravelin, L., Hu, G., Ferland, L., Richardson, P., Elias, A., Chen, L., "Detection and Analysis of Cancer Cells in Blood and Bone Marrow Using a Rare Event Imaging System", Clin. Cancer Research, 6: 434-442 (Feb., 2000)


EXAMINER


[Signature]


DATE CONSIDERED

10/4/06

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	R24	Reiner, A., Neumeister, B., Spona, J., Reiner, G., Schemper, M., Jakesz, R., "Immunocytochemical Localization of Estrogen and Progesterone Receptor and Prognosis in Human Primary Breast Cancer", Cancer Research, <u>50</u> : 7057-7061 (Nov., 1990)
	R25	Mokbel, K., Parris, C., Ghilchik, M., Williams, G., Newbold, R., "The Association Between Telomerase, Histopathological Parameters, and KI-67 Expression in Breast Cancer", Am. J. Surgery, <u>178</u> : 69-72 (1999)


EXAMINER 	DATE CONSIDERED <u>10/4/06</u>
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

Form PTO-449 (Modified) <div style="text-align: center;">  </div>	U.S. Department of Commerce Patent and Trademark Office	Serial No. 10/022,618	Group Art Unit 1642	Filing Date 12/17/2001	Atty. Docket No. Le A 35 010
	Applicant(s) Henning, et al.				

U.S. PATENT DOCUMENTS													
*		DOCUMENT NO.							DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS														
		DOCUMENT NO.							DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
													YES	NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)		
84 ↓	R26	Leek, R., Kaklamanis, L., Pezzella, F., Gatter, K., Harris, A., "bcl-2 in Normal Human Breast and Carcinoma, Association With Oestrogen Receptor-Positive, Epidermal Growth Factor Receptor-Negative Tumours and In Situ Cancer", Br. J. Cancer, <u>69</u> : 135-139 (1994)
	R27	Oshika, Y., Nakamura, M., Tokunaga, T., Fukushima, Y., Abe, Y., Ozeki, Y., Yamazaki, H., Tamaoki, N., Ueyama, Y., "Multidrug Resistance-Associated Protein and Mutant p53 Protein Expression in Non-Small Cell Lung Cancer", Mod. Pathol., <u>11</u> : 1059-1063 (1998)

EXAMINER		DATE CONSIDERED 10/4/06
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		